Carl Zeiss Meditec, a glaucoma care company, has launched Humphrey® Field Analyzer II-i (HFA II-i) with new Guided Progression Analysis™ (GPA) software. HFA II-i is to be used in determining the stage of the disease, the rate of progression and the risk of loss of vision. Eye care providers will now be able to monitor patients to prevent the loss of vision.

CIBA Vision, the eye care unit of Novartis, has announced a final global patent litigation settlement agreement with CooperVision, Inc. The agreement resolves all current patent infringement lawsuits between the two companies. CIBA Vision has licensed its Nicolson patents to CooperVision, while the latter company will pay the former a royalty on U.S. net sales of its Biofinity contact lenses until 2014 and on net sales outside the U.S. until 2016.

People who wear contact lenses sometimes face the problem of their vision fluctuating during the day. The answer to this problem may lie in the design of their contact lens, according to a new clinical study published in Optometry and Vision Science, the peer-reviewed journal of the American Academy of Optometry. The researchers indicates that their findings could be of particular relevance to people who wear soft toric contact lenses for the treatment of astigmatism, a common vision condition in which surfaces of the eye, including the cornea, have an oval shape.

STAAR Surgical Company has received approval from the Sate Food and Drug Administration (SFDA) of the People’s Republic of China to market its Visian™ Toric Implantable Collamer Lens (ICL) in the country for treating nearsightedness and astigmatism. This lens, made of a highly biocompatible material called Collamer, is minimally invasive and foldable. The ICL procedure makes an incision that is as much as 50% smaller than that made by other technologies and the lens is placed behind the iris.